Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home button

Trial Design: Pain Sections
Author Bio
Introduction
Placebo Effects
Currently selected section: Single Dose Trials
Repeated Dose Trials
Explanatory Versus Pragmatic
Dose-Response
Parallel Group Versus Crossover
Conclusion
 

 

Commentary of Eugene Laska, Statistician

Chapter 1: Clinical Trials of Pain Treatment: Single Dose Trials

 
         

What Does a "Negative" Result Mean in a Symptom Study?
Establishing "Assay Sensitivity"

Photo of DoctorThe interpretation of a "negative" result (i.e. no significant difference in primary outcome between two treatment groups of interest) differs in studies of symptoms and structural disease. Because one can objectively and reproducibly characterize and quantitate structural disease (e.g. tumor size and histology, patient dead or alive, etc.) most investigators interpret a finding of no difference between a new treatment and a comparator, given adequate sample size, to mean that there really is no difference. In contrast, a variety of influences on the way analgesic clinical trials are executed and pain is assessed sometimes make it difficult for even the most expert investigators to have their patients distinguish the effects of a potent analgesic and a placebo. Borrowing the analogy of a chemical assay, analgesic experts will not accept the validity of a finding of "no difference" between two treatments unless another internal control confirms "assay sensitivity," that the study methods can show a difference over the range of interest if one is there (Max and Laska, 1991).

The graphs in the following eight examples represent the outcomes of single-dose analgesic studies and are intended to illustrate the situations in which placebo or standard analgesic control groups are needed, and when they are less essential. Although some of the questions may seem elementary, we urge you to go through all the questions for the eight figures, because they are essential to grasping some unique features of clinical trials of symptom treatments. This is now widely applied in determining the validity of single-dose analgesic trials (Max and Laska, 1991; FDA, 1992), and appears plausible for use in the study of other symptoms and with modifications to clinical trials in which repeated doses of drugs are given over days or weeks.

Interpreting Analgesic Studies: Eight Cases Illustrating the Information Gained from Placebo and Positive Controls

Treatments were placebo, Drug X, and morphine.  The figure shows that both Drug X and Morphine gave a large amount of relief, similar to each other.  Both were statistically superior to placebo.

This and the figures to follow represent the results of a study of a single dose of analgesic given to patients with acute postoperative pain. The sum of hourly pain relief scores for four hours after a dose of analgesic (often called TOTPAR for "total pain relief") are shown for Drug X, a putative analgesic, placebo, and morphine (or another analgesic known to be effective in the condition being studied). The error bars represent standard errors of the mean, and a difference of roughly two standard errors would indicate a statistically significant difference between treatments.

 

Question 3.1

Do these data demonstrate that Drug X is an effective analgesic in this condition?

Yes          No    


Page 7 of 52
      Previous Section